Pre Procedural Biomarkers Might Predict Recurrent Atrial Fibrillation After Catheter Ablation

Pre Procedural High Serum Visfatin and Tumor Necrosis Factors Alpha Might Predict Recurrent Atrial Fibrillation After Catheter Ablation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05114772

Enrollment

117

Registered

2021-11-10

Start date

2019-07-01

Completion date

2021-08-01

Last updated

2021-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

Evaluation of the predictive value of serum levels of adipocytokines and primary phase reactant for recurrent atrial fibrillation (RAF) after catheter ablation in 26 patients had persistent and 91 patients had paroxysmal AF. During 12-m follow-up, 41 patients had RAF (35%). Patients had RAF were significantly older, had significantly higher BMI, lower ejection fraction and wider maximal left atrial diameter (LAD). Serum hs-CRP, IL-6, TNF-α, visfatin, and adiponectin levels were significantly higher in patients developed. Elevated serum levels of TNF-α, visfatin and adiponectin are a significant positive predictors for RAF.

Detailed description

Objectives: Estimation of serum levels of visfatin, adiponectin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) in patients had atrial fibrillation (AF) resistant to medical treatment and assigned to catheter ablation (CA) to evaluate these biomarkers as predictors for recurrent AF (RAF). Patients & Methods: 117 patients; 26 patients had persistent and 91 patients had paroxysmal AF underwent had clinical and echographic evaluations and gave blood samples for ELISA estimation of serum levels of studied cytokines. CA was performed through isolation of all pulmonary veins according to the stepwise procedure of ablation. Patients were re-evaluated every three months till 12-m follow-up for post-procedural RAF.

Interventions

DIAGNOSTIC_TESTMeasuring Serum bio-markers

ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Symptomatic paroxysmal or persistent AF that was resistant to medical acceptable daily dose therapy in patients who were free of

Exclusion criteria

and accepted to sign the written fully informed consent to undergo CA and to give pre-procedural blood samples.

Design outcomes

Primary

Measure	Time frame	Description
Recurrent Atrial Fibrillation	12 months	Recurrent Atrial Fibrillation after Catheter ablation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026